Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obstetrics | 9 | 2019 | 26 | 4.720 |
Why?
|
| Clinical Competence | 13 | 2019 | 325 | 3.430 |
Why?
|
| Pregnancy | 22 | 2019 | 994 | 1.900 |
Why?
|
| Delivery, Obstetric | 3 | 2017 | 58 | 1.630 |
Why?
|
| Models, Anatomic | 5 | 2019 | 39 | 1.490 |
Why?
|
| Patient Simulation | 3 | 2015 | 32 | 1.390 |
Why?
|
| Cervix Uteri | 2 | 2019 | 27 | 1.370 |
Why?
|
| Physical Examination | 2 | 2019 | 92 | 1.320 |
Why?
|
| Students, Medical | 4 | 2019 | 129 | 1.320 |
Why?
|
| Internship and Residency | 4 | 2017 | 306 | 1.240 |
Why?
|
| Clinical Clerkship | 3 | 2016 | 42 | 1.150 |
Why?
|
| Gynecology | 3 | 2017 | 17 | 1.140 |
Why?
|
| Ultrasonography, Interventional | 2 | 2017 | 53 | 1.140 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2017 | 42 | 1.120 |
Why?
|
| Acetaminophen | 2 | 2016 | 19 | 1.070 |
Why?
|
| Fetus | 2 | 2015 | 86 | 0.990 |
Why?
|
| Female | 25 | 2019 | 19859 | 0.780 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2011 | 13 | 0.760 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 40 | 0.740 |
Why?
|
| Pregnancy Complications | 4 | 2018 | 105 | 0.730 |
Why?
|
| Neutrophils | 2 | 2011 | 112 | 0.710 |
Why?
|
| Labor Stage, First | 2 | 2019 | 9 | 0.700 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 18 | 0.690 |
Why?
|
| Labor, Obstetric | 1 | 2019 | 36 | 0.680 |
Why?
|
| Learning | 1 | 2019 | 78 | 0.660 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 87 | 0.640 |
Why?
|
| Adult | 16 | 2019 | 9327 | 0.640 |
Why?
|
| Abnormalities, Multiple | 2 | 2017 | 28 | 0.620 |
Why?
|
| Swine | 2 | 2015 | 215 | 0.620 |
Why?
|
| Educational Status | 1 | 2017 | 178 | 0.570 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 6 | 0.570 |
Why?
|
| Humans | 24 | 2019 | 31836 | 0.570 |
Why?
|
| Family Practice | 1 | 2017 | 51 | 0.560 |
Why?
|
| Fetal Blood | 1 | 2016 | 38 | 0.550 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2018 | 23 | 0.540 |
Why?
|
| Cerclage, Cervical | 2 | 2013 | 6 | 0.540 |
Why?
|
| Fetal Movement | 1 | 2015 | 1 | 0.520 |
Why?
|
| Educational Measurement | 4 | 2017 | 118 | 0.520 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 13 | 0.510 |
Why?
|
| Abortion, Induced | 1 | 2015 | 6 | 0.500 |
Why?
|
| Radiology | 1 | 2015 | 41 | 0.500 |
Why?
|
| Lung Diseases | 1 | 2014 | 47 | 0.470 |
Why?
|
| Cesarean Section | 3 | 2011 | 112 | 0.460 |
Why?
|
| RNA, Messenger | 3 | 2011 | 508 | 0.460 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 55 | 0.430 |
Why?
|
| Analgesics | 2 | 2011 | 109 | 0.420 |
Why?
|
| Lung | 1 | 2014 | 255 | 0.410 |
Why?
|
| Surgical Stapling | 1 | 2011 | 12 | 0.400 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 771 | 0.400 |
Why?
|
| Receptors, Opioid, delta | 4 | 2004 | 12 | 0.390 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2011 | 3 | 0.380 |
Why?
|
| Blood Cells | 1 | 2010 | 9 | 0.380 |
Why?
|
| Curriculum | 3 | 2017 | 208 | 0.360 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 66 | 0.360 |
Why?
|
| Placenta | 1 | 2010 | 74 | 0.350 |
Why?
|
| Pregnancy Outcome | 2 | 2010 | 90 | 0.350 |
Why?
|
| Fontan Procedure | 1 | 2009 | 2 | 0.350 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 31 | 0.340 |
Why?
|
| Pain, Postoperative | 1 | 2011 | 178 | 0.340 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 24 | 0.340 |
Why?
|
| Models, Animal | 3 | 2015 | 164 | 0.330 |
Why?
|
| Prospective Studies | 3 | 2017 | 2277 | 0.280 |
Why?
|
| Animals | 10 | 2015 | 7450 | 0.280 |
Why?
|
| Receptors, Opioid, mu | 2 | 2004 | 31 | 0.280 |
Why?
|
| Male | 9 | 2019 | 19091 | 0.250 |
Why?
|
| Analgesics, Opioid | 3 | 2004 | 231 | 0.240 |
Why?
|
| Young Adult | 3 | 2019 | 2603 | 0.240 |
Why?
|
| Gestational Age | 2 | 2016 | 120 | 0.220 |
Why?
|
| Uterine Cervical Incompetence | 2 | 2013 | 3 | 0.220 |
Why?
|
| Morphine Dependence | 1 | 2002 | 1 | 0.220 |
Why?
|
| Enkephalins | 1 | 2002 | 10 | 0.220 |
Why?
|
| Chorionic Villi Sampling | 2 | 2013 | 3 | 0.220 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2003 | 20 | 0.220 |
Why?
|
| Protein Precursors | 1 | 2002 | 22 | 0.220 |
Why?
|
| Morphine | 1 | 2002 | 44 | 0.210 |
Why?
|
| Brain | 3 | 2004 | 949 | 0.200 |
Why?
|
| Uterine Diseases | 1 | 2018 | 20 | 0.160 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 518 | 0.160 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2017 | 4 | 0.150 |
Why?
|
| Fetal Death | 1 | 2017 | 9 | 0.150 |
Why?
|
| Checklist | 1 | 2017 | 38 | 0.150 |
Why?
|
| Colon | 1 | 2017 | 51 | 0.150 |
Why?
|
| Gelatin | 1 | 2017 | 29 | 0.140 |
Why?
|
| Term Birth | 1 | 2016 | 5 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2016 | 51 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2017 | 78 | 0.130 |
Why?
|
| Urinary Bladder | 1 | 2017 | 182 | 0.130 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 3 | 2004 | 5 | 0.130 |
Why?
|
| Linear Models | 1 | 2016 | 449 | 0.130 |
Why?
|
| Respiration | 1 | 2015 | 27 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 180 | 0.130 |
Why?
|
| Teaching | 1 | 2015 | 61 | 0.120 |
Why?
|
| Physicians | 1 | 2017 | 157 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2015 | 184 | 0.120 |
Why?
|
| Models, Biological | 1 | 2017 | 391 | 0.120 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Amniocentesis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Mice | 6 | 2004 | 2476 | 0.110 |
Why?
|
| Perinatology | 1 | 2012 | 2 | 0.100 |
Why?
|
| Steel | 1 | 2011 | 2 | 0.100 |
Why?
|
| Mice, Knockout | 5 | 2004 | 444 | 0.100 |
Why?
|
| Polyglycolic Acid | 1 | 2011 | 33 | 0.100 |
Why?
|
| Sutures | 1 | 2011 | 20 | 0.100 |
Why?
|
| Absorbable Implants | 1 | 2011 | 24 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 589 | 0.100 |
Why?
|
| Pregnancy Trimesters | 1 | 2010 | 3 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 14 | 0.090 |
Why?
|
| North Carolina | 1 | 2015 | 1514 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2015 | 1824 | 0.090 |
Why?
|
| Rectus Abdominis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 186 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 142 | 0.090 |
Why?
|
| Hematoma | 1 | 2010 | 26 | 0.090 |
Why?
|
| Wound Healing | 1 | 2011 | 185 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2010 | 45 | 0.090 |
Why?
|
| Naloxone | 3 | 2004 | 26 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 404 | 0.090 |
Why?
|
| Prognosis | 1 | 2014 | 1498 | 0.090 |
Why?
|
| Obstetric Labor, Premature | 1 | 2009 | 10 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 231 | 0.090 |
Why?
|
| Autoradiography | 3 | 2004 | 45 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 895 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 493 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1323 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2009 | 665 | 0.070 |
Why?
|
| Drug Tolerance | 2 | 2002 | 32 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 2271 | 0.060 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2004 | 24 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2004 | 16 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 124 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3488 | 0.060 |
Why?
|
| Sulfur Radioisotopes | 1 | 2003 | 6 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 12 | 0.050 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2003 | 14 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2002 | 12 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2002 | 17 | 0.050 |
Why?
|
| Convulsants | 1 | 2002 | 3 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2002 | 12 | 0.050 |
Why?
|
| Naltrexone | 1 | 2002 | 18 | 0.050 |
Why?
|
| Adolescent | 1 | 2010 | 3511 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 59 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2002 | 130 | 0.050 |
Why?
|
| Narcotic Antagonists | 3 | 2004 | 39 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2018 | 23 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 2018 | 24 | 0.040 |
Why?
|
| Education, Medical | 1 | 2012 | 68 | 0.020 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 2 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
| Endorphins | 1 | 2004 | 1 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2004 | 7 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 12 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 5 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 31 | 0.020 |
Why?
|
| Cell Count | 1 | 2004 | 47 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2004 | 79 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2004 | 39 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 201 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 168 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 184 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 461 | 0.010 |
Why?
|
| Benzomorphans | 1 | 2002 | 1 | 0.010 |
Why?
|
| Benzylidene Compounds | 1 | 2002 | 7 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 2002 | 14 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 33 | 0.010 |
Why?
|
| Benzamides | 1 | 2002 | 49 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 130 | 0.010 |
Why?
|
| Piperazines | 1 | 2002 | 54 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 59 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 468 | 0.010 |
Why?
|
| Middle Aged | 1 | 2012 | 11824 | 0.010 |
Why?
|